Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CCKAR | P32238 | 2/20 | 0.39 |
| ▸ | CCKBR | P32239 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924903 | 1.00 | MDM2 (0.44) | MDM2HDAC8CTSSCTSKCTSL | |
| SCHEMBL23925017 | 0.98 | MDM2 (0.45) | MDM2HDAC8CTSSCTSKCTSL | |
| SCHEMBL23925019 | 0.98 | MDM2 (0.45) | MDM2HDAC8CTSSCTSKCTSL | |
| SCHEMBL21683283 | 0.86 | MDM2 (0.41) | MDM2EPHX2SCN9A | |
| SCHEMBL23924843 | 0.85 | EPHX2 (0.43) | CTSSCTSKCTSLCTSBEPHX2 | |
| SCHEMBL23924845 | 0.85 | EPHX2 (0.43) | CTSSCTSKCTSLCTSBEPHX2 | |
| SCHEMBL21683221 | 0.84 | MDM2 (0.41) | MDM2EPHX2SCN9A | |
| SCHEMBL23925185 | 0.82 | EPHX2 (0.43) | EPHX2 | |
| SCHEMBL23925183 | 0.82 | EPHX2 (0.43) | EPHX2 | |
| SCHEMBL23924770 | 0.82 | TLR2 (0.47) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | MDM2 1722/4885HDAC8 202/4885CTSS 1930/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | MDM2 1722/4885HDAC8 202/4885CTSS 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.